Outcomes and potential surrogate markers for future clinical trials of non‐alcoholic steatohepatitis cirrhosis-Reference-Cited by-同舟云学术

Outcomes and potential surrogate markers for future clinical trials of non‐alcoholic steatohepatitis cirrhosis

Published:2021-07-21 Issue:9 Volume:41 Page:1999-2008
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Rivera‐Esteban Jesús¹²^ORCID,Armandi Angelo³,Augustin Salvador¹⁴,Bugianesi Elisabetta³

Affiliation:

1. Liver Unit Department of Internal Medicine Vall d’Hebron Hospital UniversitariVall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus Barcelona Spain

2. Universitat Autònoma de Barcelona Bellaterra Spain

3. Department of Medical Sciences Division of Gastroenterology and Hepatology A.O. Città della Salute e della Scienza di Torino University of Turin Turin Italy

4. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) Instituto de Salud Carlos III Madrid Spain

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.15013

Reference64 articles.

1. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

2. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆

3. Long term prognosis of fatty liver: risk of chronic liver disease and death

4. The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study

5. Long-term follow-up of patients with NAFLD and elevated liver enzymes

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Variability of transient elastography-based spleen stiffness performed at 100 Hz;European Radiology Experimental;2023-12-12

2. Soluble Guanylyl Cyclase Activator BI 685509 Reduces Portal Hypertension and Portosystemic Shunting in a Rat Thioacetamide-Induced Cirrhosis Model;Journal of Pharmacology and Experimental Therapeutics;2023-05-25

3. An international multidisciplinary consensus statement on MAFLD and the risk of CVD;Hepatology International;2023-05-19

4. Insights into the pharmacological and therapeutic effects of apigenin in liver injuries and diseases;Heliyon;2023-05

5. The rationale and study design of two phase II trials examining the effects of BI 685509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis;Trials;2023-04-24